Open AccessBioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients:
Author(s) -
E. Ignatova,
Olga Burdaeva,
М. В. Копп
Publication year - 2016
Publication title -
journal of modern oncology
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/1815-1434_2016.2.39-47
Subject(s) - trastuzumab , medicine , paclitaxel , oncology , bioequivalence , metastatic breast cancer , breast cancer , cancer , pharmacokinetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom